o(6)-benzylguanine has been researched along with Mycosis Fungoides in 2 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
Mycosis Fungoides: A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached." | 9.24 | Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. ( Carlson, S; Chan, DV; Cooper, KD; Dowlati, A; Fu, P; Gerson, SL; Groft, S; Honda, K; Lu, K; McCormick, TS; Rosenjack, J; Tacastacas, JD, 2017) |
| "A total of 21 adult patients (11 male, 10 female)with early-stage (IA-IIA) refractory CTCL, mycosis fungoides type, treated with topical carmustine following intravenous O6-benzylguanine." | 9.16 | Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. ( Apisarnthanarax, N; Carlson, S; Chan, DV; Cooper, KD; Fu, P; Gerson, SL; Gilliam, AC; Liu, L; Remick, SC; Stevens, SR; Szabo, SK; Wood, GS, 2012) |
| "In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached." | 5.24 | Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. ( Carlson, S; Chan, DV; Cooper, KD; Dowlati, A; Fu, P; Gerson, SL; Groft, S; Honda, K; Lu, K; McCormick, TS; Rosenjack, J; Tacastacas, JD, 2017) |
| "A total of 21 adult patients (11 male, 10 female)with early-stage (IA-IIA) refractory CTCL, mycosis fungoides type, treated with topical carmustine following intravenous O6-benzylguanine." | 5.16 | Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. ( Apisarnthanarax, N; Carlson, S; Chan, DV; Cooper, KD; Fu, P; Gerson, SL; Gilliam, AC; Liu, L; Remick, SC; Stevens, SR; Szabo, SK; Wood, GS, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tacastacas, JD | 1 |
| Chan, DV | 2 |
| Carlson, S | 2 |
| Gerson, SL | 2 |
| Dowlati, A | 1 |
| Fu, P | 2 |
| Lu, K | 1 |
| Groft, S | 1 |
| Rosenjack, J | 1 |
| Honda, K | 1 |
| McCormick, TS | 1 |
| Cooper, KD | 2 |
| Apisarnthanarax, N | 1 |
| Wood, GS | 1 |
| Stevens, SR | 1 |
| Liu, L | 1 |
| Szabo, SK | 1 |
| Gilliam, AC | 1 |
| Remick, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma[NCT00961220] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2010-02-01 | Completed | ||
| Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma[NCT00003613] | Phase 1 | 20 participants (Anticipated) | Interventional | 1999-04-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Based on changes in modified SWAT assessment, patient responses will be classified as complete clinical response (CCR), partial response (PR), stable disease (SD), or progressive disease (PD). SWAT provides an accurate and reproducible assessment of cutaneous disease involvement based on body surface area of involvement and lesional thickness.~CCR: No evidence of disease, 100% improvement for a duration of at least 4 weeks. PR: Greater than or equal to 50% decrease in SWAT score compared to baseline and improvement is maintained for at least 4 weeks. SD: Less than 50% decrease in SWAT score compared to baseline. PD: Increase of greater or equal to 25% of the SWAT score compared to baseline while the patient is actively taking the study drug" (NCT00961220)
Timeframe: Up to 2 weeks after completion of study treatment
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete Clinical Response-confirmed | Complete Clinical Response-unconfirmed | Partial Response | Progressive Disease | |
| Treatment (O6-benzylguanine, Carmustine) | 6 | 2 | 8 | 1 |
2 trials available for o(6)-benzylguanine and Mycosis Fungoides
| Article | Year |
|---|---|
Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemoth | 2017 |
Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2012 |